Results 221 to 230 of about 141,907 (307)
ABSTRACT Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable‐risk in the absence of FLT3‐ITD. In the European LeukemiaNet (ELN) 2024 risk‐classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN),
Fieke W. Hoff +44 more
wiley +1 more source
Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy. [PDF]
Collins JM, Tukvadze N, Kempker RR.
europepmc +1 more source
ABSTRACT Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first‐line therapy when combined with intensive chemotherapy in both FLT3 ITD‐negative and positive AML.
Teresa Bernal +29 more
wiley +1 more source
Association of maternal immunoglobulin G levels with pregnancy outcomes in primary immunodeficiency: A retrospective single-center study. [PDF]
Gerek ME +9 more
europepmc +1 more source
ABSTRACT Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic ...
Betty K. Hamilton +11 more
wiley +1 more source
Age and Seasonal Variation in Allergen Sensitivity Among Children: A Comprehensive Analysis of Food and Environmental Allergens. [PDF]
Hashmi B +5 more
europepmc +1 more source
ABSTRACT Dordaviprone is a first‐in‐class small‐molecule imipridone. In preclinical studies, it is active against leukemia cells harboring a TP53 mutation or complex karyotype and leukemia stem cells while sparing normal bone marrow cells. This study aimed to determine the safety of dordaviprone maintenance after allogeneic hematopoietic cell ...
Vijaya Raj Bhatt +8 more
wiley +1 more source
From anaphylaxis to eosinophilic esophagitis during omalizumab treatment in a boy with severe asthma and food allergy: a case report. [PDF]
Jedynak-Wąsowicz U +2 more
europepmc +1 more source
ABSTRACT Hydroxyurea (HU) is the most widely prescribed disease‐modifying treatment in sickle cell disease (SCD), though treatment responses vary due to metabolism and adherence. We examined HU blood levels and treatment response in patients with homozygous sickle cell disease (HbSS).
Sigrid van der Veen +26 more
wiley +1 more source
Update on occupational contact urticaria: a systematic narrative review. [PDF]
Bizjak-Suran M +2 more
europepmc +1 more source

